While the current management may be very astute at carrying out research and developing potentially great drug/drug platforms, they ARE NOT showing any signs of success when it comes to commercialisation of these products.
Could explain why HQ haven't been able to strike a DEP® Cabazitaxel and DEP® Docetaxel license deal to date - they may not be up to the challenge or perhaps the results perused under an NDA by multiple pharma groups don't stack up ?
How can a company tout consistently over the years that they are in 'confidential commercial negotiations with severalpotential partners' and come up empty handed year after year ? They claim these negotiations are ongoing in most ASX announcements - here's an example from 2021 off the back of the interim phase 2 DEP® Cabazitaxel clinical trial results
Looking like another week of absolutely nothing coming out of Starpharma again as another Friday is upon us .... not even a further update on AACR 2 days in as some hoped earlier in the week
Poster Session A on Thursday, October 12, from 12:30-4 P.M.
Poster Session B on Friday, October 13, from 12:30-4 P.M
Poster Session C on Saturday, October 14 from 12:30-4 P.M.
